Clinical Trials Browser

Leukemia × Bortezomib × Myeloid × Clear all

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

NCT01891968 2018-04-23

Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation

Phase 2 Completed

15 enrolled 7 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

NCT00818649 2017-12-28

Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 2 Terminated

16 enrolled 7 charts

Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT00624936 2017-08-22

Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

Phase 1 Completed

23 enrolled

MyeloidOther hematologic neoplasm

Congenital Abnormalities, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT01323920 2017-05-30

Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors

Phase 2 Completed

35 enrolled 9 charts

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes

NCT01075425 2016-04-15

Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome

Phase 1 Completed

41 enrolled

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00437086 2014-10-17

Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders

Phase EARLY_PHASE1 Completed

30 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

Clinical Trials

Bortezomib in Treating Patients With Chronic Myelogenous Leukemia

Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation

Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors

Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome

Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders